INNOVATE (VATE) Q1 2026 earnings summary

Executive summary

• Q1 2026 consolidated revenue rose 33% year-over-year to $364.8 million, driven by strong Infrastructure segment performance, while Life Sciences and Spectrum segments saw revenue declines.

• Net loss attributable to shareholders narrowed to between $16.8 million and $17.2 million, improving from losses of $24.5 million to $25.8 million in Q1 2025.

• Adjusted EBITDA increased to $19.7 million from $7.2 million, reflecting higher gross profit and operational improvements.

• Infrastructure segment delivered robust sales, backlog, and pipeline momentum; Life Sciences achieved regulatory milestones; Spectrum faced advertising softness but advanced strategic projects.

• Substantial doubt exists about the company's ability to continue as a going concern due to upcoming debt maturities and covenant risks.

Financial highlights

• Infrastructure revenue grew 35.1% year-over-year to $357.9 million; Life Sciences revenue fell to $1.6 million; Spectrum revenue declined to $5.3 million.

• Gross profit increased to $53.5 million from $45.5 million year-over-year.

• Adjusted EBITDA for Infrastructure was $23.0 million, Life Sciences $(2.0) million, Spectrum $0.7 million.

• Cash and cash equivalents at quarter-end: $134.6 million, up from $112.1 million at year-end 2025.

• Total principal outstanding indebtedness: $699 million as of March 31, 2026.

Outlook and guidance

• Infrastructure backlog and pipeline remain robust, with early progress building 2027 backlog and strong visibility into 2026 and 2027.

• Life Sciences expects further regulatory and commercial milestones, with ongoing clinical studies and global expansion.

• Spectrum anticipates improved performance as regulatory tailwinds and strategic investments take effect, with focus on expanding its national footprint.

• Management is pursuing asset sales, debt refinancing, and capital raises to address liquidity and covenant risks.

• No formal financial guidance provided; compliance with debt milestones and asset sales are critical for ongoing operations.